Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8AOC1
|
|||
| Drug Name |
AMG 330
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1], [2] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | Inhibitor | [3] |
| T-cell surface glycoprotein CD3 (CD3) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.